AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$CVKD

Pham Quang X sold $3K of CVKD

Pham Quang X (CEO and Chairman) sold 652 shares of Cadrenal Therapeutics, Inc. (CVKD) at an average of $4.72 ($4.46–$5.01) across 2 trades over 2026-05-29 to 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pham Quang X
Published Jun 3, 2026, 12:34 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CVKD
Neutral
high confidence
Mentioned
$CVKD
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CVKDNeutralLow
01

Why it matters

The transaction is a primary disclosure but trivial in size.

02

Market read

Insider sale is minor; unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 2/10Novelty 2/10Timing: today

Background

Form 4 filings disclose insider trades; small sales are routine.

Company-level read

Ticker impact

$CVKDNeutralHigh confidence
Context

CEO Pham Quang X sold 652 shares for $3,074.57 via a 10b5-1 plan.

Expected impact

likely slight downward pressure as market prices in the insider sale.

Evidence & confidence

The sale is small relative to total holdings and market cap, so impact is limited.

Market effects

Sector

No broader sector impact; typical insider transaction.

Regional

Limited to US biotech investors.

Global

Minimal.

Counterpoint

What could challenge this read

The sale could be a signal of insider confidence if viewed as routine 10b5-1 execution.

Key entities

  • Company
    Cadrenal Therapeutics, Inc.

    Biotech firm listed on NASDAQ under CVKD.

  • Person
    Pham Quang X

    CEO and Chairman of Cadrenal Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CVKD insider trading history →

Related articles

AUG 13
$CVKDMed

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the…

Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio org

SEC EDGAR 8-K6 min
JUL 13
$CVKDMedAI 8/10

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Cadrenal Therapeutics (Nasdaq: CVKD) said Phase 2 late-breaking data for its 12-LOX inhibitor CAD-1005 were presented at ISTH 2026. In HIT, CAD-1005 showed an absolute reduction of more than 25% in new or worsening thrombotic events vs placebo (50% vs >75%) and no CAD-1005-attributable serious adverse events or deaths. Company cites $2B peak annual revenue potential.

manilatimes.net4 min
JUN 22
$CVKDMed

Cadrenal Advances Tecarfarin Toward FDA Rare Pediatric Disease Filing In Kawasaki Disease

Cadrenal Therapeutics said it plans to file for FDA Rare Pediatric Disease designation for tecarfarin in children with Kawasaki disease who develop coronary artery aneurysms. The company says tecarfarin is designed to provide more stable anticoagulation than warfarin. If approved, Cadrenal could receive a Priority Review Voucher, which it notes has sold for $180M–$205M.

rttnews.com5 min
SEP 29
$COURMedAI 8/10

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $11.4M of COUR (indirect holdings)

Pale Fire Capital SE purchased 2,332,742 indirectly-held shares of Coursera, Inc. (COUR) at an average of $4.87 ($4.61–$5.06, $11.36M total) across 2 trades over 2026-09-25 to 2026-09-29. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min